We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+15.44%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$855M
AUM Growth
-$19.9M
Cap. Flow
-$111M
Cap. Flow %
-12.98%
Top 10 Hldgs %
29.46%
Holding
101
New
12
Increased
17
Reduced
38
Closed
8

Top Buys

Rank Stock Value
1
LIVN icon
LivaNova
LIVN
+$11.2M
2
ABMD
Abiomed Inc
ABMD
+$9.03M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.67M
4
EXAS
Exact Sciences
EXAS
+$8.51M
5
MGNX icon
MacroGenics
MGNX
+$7.35M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$18.1M
2
INCY icon
Incyte
INCY
+$13.5M
3
CELG
Celgene Corp
CELG
+$13.1M
4
SAGE
Sage Therapeutics
SAGE
+$12.4M
5
EXEL icon
Exelixis
EXEL
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 93.64%
2 Technology 0.15%
3 Energy 0.14%
4 Financials 0.1%
5 Communication Services 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
101
DELISTED
Loxo Oncology, Inc
LOXO
– –
-10,000
Closed -$1.4M
1 2 3 4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rhenman & Partners Asset Management held 101 positions worth $855M, down 2.3% from $875M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $111M in Q1 2019, closing 8 positions and reducing 38 holdings. Its most notable exit was Biogen, an estimated $18.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Technology and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Exact Sciences worth $8.66M.

  • Rhenman & Partners Asset Management's largest Q1 2019 buy was Exact Sciences: 100,000 shares worth $8.66M.
  • Rhenman & Partners Asset Management added most to LivaNova in Q1 2019, an estimated $11.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2019 reduction was Incyte, cutting an estimated $13.5M.
  • Rhenman & Partners Asset Management fully exited Biogen in Q1 2019, selling an estimated $18.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $855M portfolio in Q1 2019.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 8 in Q1 2019.
  • Rhenman & Partners Asset Management's portfolio value fell 2.3% quarter-over-quarter to $855M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2019, filed 11 Apr 2019.